Dear friend,
Last week, our friends at the Ethics and Public Policy Center (EPPC) released a groundbreaking and shocking new study on the abortion-inducing drug mifepristone. Its most alarming finding is that more than one in 10 women who take the abortion pill experience serious complications, including hemorrhaging, infection, and sepsis—a rate dramatically higher than what the FDA has disclosed to the public.
The chemical abortion drug regimen, which includes mifepristone, has always been marketed by the abortion industry as safe and “effective.” But this new study from the folks at EPPC says the exact opposite.
It is the largest study of mifepristone ever conducted, analyzing 865,000 mifepristone-induced abortions. And its findings are both clear and troubling: the real-world complication rate for prescribed mifepristone abortions stands at 10.93%, which is 22 times higher than the "less than 0.5%" figure reported in FDA-approved clinical trials.
This comes on the heels of a two-decade effort by the FDA to make the abortion drug regimen more easily accessible to women by removing required doctor visits and other important safeguards around the drugs. This deregulation of seriously risky drugs has put millions of American mothers in danger.
We at FPA believe Americans deserve better from their government—that's why our CEO Craig DeRoche signed us onto a letter sent to President Trump, along with over 50 other pro-life organizations, urging immediate action to address the dangers of mifepristone. This letter calls for the President to support state pro-life laws, reconsider the FDA's approval of mifepristone, and, at minimum, reinstate the original safety protocols established in 2000 that protected American women.
It is through our After Roe campaign that we pursue policy objectives like these in the states and in Washington, D.C. Your support makes that possible. Thank you for supporting us as we work to ensure our governments at the federal and state level actually protect vulnerable mothers and their babies.
Sincerely,
